Skip to content
ClinCalc Pro
Menu
Antispasmodic + bulk-forming laxative

Mebeverine with ispaghula husk

Brand names: Fybogel Mebeverine

This combination pairs the antispasmodic mebeverine with the bulk-forming agent ispaghula husk for irritable bowel syndrome where both cramping pain and altered, particularly constipation-predominant, bowel habit are present.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Mebeverine relaxes intestinal smooth muscle to relieve spasm, while ispaghula husk is a soluble fibre that absorbs water to increase faecal bulk and normalise stool consistency and transit.

Prescribing in practice

  • Ispaghula must be taken with plenty of fluid and avoided in patients with intestinal obstruction, faecal impaction or difficulty swallowing, as inadequate fluid can cause oesophageal or bowel obstruction.
  • Mebeverine is contraindicated in paralytic ileus; the bulking component should not be taken immediately before lying down or going to bed.
  • Bulk-forming fibre may reduce absorption of some co-administered oral drugs, so timing should be considered.

Monitoring

No routine laboratory monitoring is needed; assess bowel habit and symptom response and reconsider the diagnosis if alarm features arise.

Counselling the patient

  • Take each dose with a full glass of water and not right before bedtime.
  • It may take a little time to settle your bowel pattern; keep up your fluid intake.
  • Report worsening pain, swallowing difficulty, bleeding or weight loss.

Evidence & guidelines

NICE supports soluble fibre such as ispaghula and antispasmodics in irritable bowel syndrome, while advising against insoluble bran, which can worsen symptoms.

Reference: NICE CG61; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.